Companies in the News

Vir Biotech IDs Two Antibodies That Could Be Effective in Preventing and Treating COVID-19

San Francisco-based Vir Biotechnology indicated it has identified several human monoclonal antibody (mAb) candidates against SARS-CoV-2, the virus causing COVID-19. In the interest of saving time, the company’s lead development was transferred to WuXi Biologics and Biogen several weeks ago with human trials likely to begin in the next three to five months. The lead antibody’s ability to neutralize the SARS-CoV-2 live virus has been confirmed in two different laboratories. It binds to an epitope—the specific part of an antigen molecule on the virus—on SARS-CoV-2 that is also seen on the SARS-CoV-1 virus that causes SARS. This means the antigen is highly conserved and less likely to disappear

CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series

Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors $40 Million Raised by CERo to Facilitate Preclinical and Clinical Development South San Francisco, Calif. – March 18, 2020 – CERo Therapeutics, Inc., a privately held biopharmaceutical company, today announced a research collaboration with Lyell Immunopharma, Inc. to develop next generation cell-based immunotherapies for solid tumors. At the same time, CERo announced the completion of a $40 million Series A private financing. Collaboration Agreement with Lyell Immunopharma Under the terms of the agreement, CERo and Lyell will collaborate to pursue proof-of-concept studies for a new class of cell-based the

CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series

-- Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors -- -- $40 Million Raised by CERo to Facilitate Preclinical and Clinical Development -- SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- CERo Therapeutics, Inc., a privately held biopharmaceutical company, today announced a research collaboration with Lyell Immunopharma, Inc. to develop next generation cell-based immunotherapies for solid tumors. At the same time, CERo announced the completion of a $40 million Series A private financing. Collaboration Agreement with Lyell Immunopharma Under the terms of the agreement, CERo and Lyell will collaborate to pursue proof-of-concept studies for